136 related articles for article (PubMed ID: 19473573)
1. Differential association of the N-propeptide of collagen IIA (PIIANP) and collagen II C-telopeptide (CTX-II) with synovitis and erosions in early and longstanding rheumatoid arthritis.
Christensen AF; Lottenburger T; Lindegaard H; Christgau S; Hørslev-Petersen K; Junker P
Clin Exp Rheumatol; 2009; 27(2):307-14. PubMed ID: 19473573
[TBL] [Abstract][Full Text] [Related]
2. Uncoupling of collagen II metabolism in newly diagnosed, untreated rheumatoid arthritis is linked to inflammation and antibodies against cyclic citrullinated peptides.
Christensen AF; Hørslev-Petersen K; Christgau S; Lindegaard HM; Lottenburger T; Junker K; Hetland ML; Stengaard-Pedersen K; Jacobsen S; Ellingsen T; Andersen LS; Hansen I; Skjødt H; Pedersen JK; Lauridsen UB; Svendsen AJ; Tarp U; Pødenphant J; Heegaard NH; Vestergaard A; Jurik AG; Ostergaard M; Junker P
J Rheumatol; 2010 Jun; 37(6):1113-20. PubMed ID: 20436079
[TBL] [Abstract][Full Text] [Related]
3. A 5-yr longitudinal study of type IIA collagen synthesis and total type II collagen degradation in patients with knee osteoarthritis--association with disease progression.
Sharif M; Kirwan J; Charni N; Sandell LJ; Whittles C; Garnero P
Rheumatology (Oxford); 2007 Jun; 46(6):938-43. PubMed ID: 17387119
[TBL] [Abstract][Full Text] [Related]
4. Serum levels of type IIA procollagen amino terminal propeptide (PIIANP) are decreased in patients with knee osteoarthritis and rheumatoid arthritis.
Rousseau JC; Zhu Y; Miossec P; Vignon E; Sandell LJ; Garnero P; Delmas PD
Osteoarthritis Cartilage; 2004 Jun; 12(6):440-7. PubMed ID: 15135140
[TBL] [Abstract][Full Text] [Related]
5. Uncoupling of type II collagen synthesis and degradation predicts progression of joint damage in patients with knee osteoarthritis.
Garnero P; Ayral X; Rousseau JC; Christgau S; Sandell LJ; Dougados M; Delmas PD
Arthritis Rheum; 2002 Oct; 46(10):2613-24. PubMed ID: 12384919
[TBL] [Abstract][Full Text] [Related]
6. Cartilage collagen type II seromarker patterns in axial spondyloarthritis and psoriatic arthritis: associations with disease activity, smoking and HLA-B27.
Munk HL; Gudmann NS; Christensen AF; Ejstrup L; Sorensen GL; Loft AG; Bay-Jensen AC; Siebuhr AS; Junker P
Rheumatol Int; 2016 Apr; 36(4):541-9. PubMed ID: 26620690
[TBL] [Abstract][Full Text] [Related]
7. Association of baseline levels of urinary glucosyl-galactosyl-pyridinoline and type II collagen C-telopeptide with progression of joint destruction in patients with early rheumatoid arthritis.
Garnero P; Gineyts E; Christgau S; Finck B; Delmas PD
Arthritis Rheum; 2002 Jan; 46(1):21-30. PubMed ID: 11817593
[TBL] [Abstract][Full Text] [Related]
8. Association of baseline levels of markers of bone and cartilage degradation with long-term progression of joint damage in patients with early rheumatoid arthritis: the COBRA study.
Garnero P; Landewé R; Boers M; Verhoeven A; Van Der Linden S; Christgau S; Van Der Heijde D; Boonen A; Geusens P
Arthritis Rheum; 2002 Nov; 46(11):2847-56. PubMed ID: 12428224
[TBL] [Abstract][Full Text] [Related]
9. Rapid and sustained improvement in bone and cartilage turnover markers with the anti-interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a substudy of the multicenter double-blind, placebo-controlled trial of tocilizumab in inadequate responders to methotrexate alone.
Garnero P; Thompson E; Woodworth T; Smolen JS
Arthritis Rheum; 2010 Jan; 62(1):33-43. PubMed ID: 20039425
[TBL] [Abstract][Full Text] [Related]
10. Circadian pattern and the effect of standardized physical exercise on procollagen IIA N-peptide (PIIANP) in rheumatoid arthritis at different stages and in healthy individuals.
Christensen AF; Lottenburger T; Lindegaard HM; Junker K; Hørslev-Petersen K; Junker P
Biomarkers; 2010 Feb; 15(1):80-5. PubMed ID: 19814628
[TBL] [Abstract][Full Text] [Related]
11. Hyaluronan derivative HYMOVIS® increases cartilage volume and type ii collagen turnover in osteoarhritic knee: data from MOKHA study.
Henrotin Y; Bannuru R; Malaise M; Ea HK; Confavreux C; Bentin J; Urbin-Choffray D; Conrozier T; Brasseur JP; Thomas P; Hick AC; Marinello A; Giordan N; Richette P
BMC Musculoskelet Disord; 2019 Jun; 20(1):293. PubMed ID: 31215422
[TBL] [Abstract][Full Text] [Related]
12. Urinary type II collagen helical peptide (HELIX-II) as a new biochemical marker of cartilage degradation in patients with osteoarthritis and rheumatoid arthritis.
Charni N; Juillet F; Garnero P
Arthritis Rheum; 2005 Apr; 52(4):1081-90. PubMed ID: 15818703
[TBL] [Abstract][Full Text] [Related]
13. Urinary type II collagen C-terminal peptide is associated with synovitis and predicts structural bone loss in very early inflammatory arthritis.
Freeston JE; Garnero P; Wakefield RJ; Hensor EM; Conaghan PG; Emery P
Ann Rheum Dis; 2011 Feb; 70(2):331-3. PubMed ID: 20980286
[TBL] [Abstract][Full Text] [Related]
14. Heritability assessment of cartilage metabolism. A twin study on circulating procollagen IIA N-terminal propeptide (PIIANP).
Munk HL; Svendsen AJ; Hjelmborg Jv; Sorensen GL; Kyvik KO; Junker P
Osteoarthritis Cartilage; 2014 Aug; 22(8):1142-7. PubMed ID: 25008205
[TBL] [Abstract][Full Text] [Related]
15. Arthritis instantaneously causes collagen type I and type II degradation in patients with early rheumatoid arthritis: a longitudinal analysis.
Landewé RB; Geusens P; van der Heijde DM; Boers M; van der Linden SJ; Garnero P
Ann Rheum Dis; 2006 Jan; 65(1):40-4. PubMed ID: 16126801
[TBL] [Abstract][Full Text] [Related]
16. Increased urinary type II collagen C-telopeptide levels in Tunisian patients with knee osteoarthritis.
Kalai E; Bahlous A; Charni N; Bouzid K; Sahli H; Chelly M; Meddeb M; Zouari B; Abdelmoula J; Sellami S
Clin Lab; 2012; 58(3-4):209-15. PubMed ID: 22582493
[TBL] [Abstract][Full Text] [Related]
17. Serum concentrations of formation (PINP) and resorption (Ctx) bone turnover markers in rheumatoid arthritis.
Wisłowska M; Jakubicz D; Stepień K; Cicha M
Rheumatol Int; 2009 Oct; 29(12):1403-9. PubMed ID: 19219607
[TBL] [Abstract][Full Text] [Related]
18. Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis.
Chopin F; Garnero P; le Henanff A; Debiais F; Daragon A; Roux C; Sany J; Wendling D; Zarnitsky C; Ravaud P; Thomas T
Ann Rheum Dis; 2008 Mar; 67(3):353-7. PubMed ID: 17644538
[TBL] [Abstract][Full Text] [Related]
19. Radiographic joint damage in rheumatoid arthritis is associated with differences in cartilage turnover and can be predicted by serum biomarkers: an evaluation from 1 to 4 years after diagnosis.
Verstappen SM; Poole AR; Ionescu M; King LE; Abrahamowicz M; Hofman DM; Bijlsma JW; Lafeber FP;
Arthritis Res Ther; 2006; 8(1):R31. PubMed ID: 16507130
[TBL] [Abstract][Full Text] [Related]
20. Markers for type II collagen breakdown predict the effect of disease-modifying treatment on long-term radiographic progression in patients with rheumatoid arthritis.
Landewé R; Geusens P; Boers M; van der Heijde D; Lems W; te Koppele J; van der Linden S; Garnero P
Arthritis Rheum; 2004 May; 50(5):1390-9. PubMed ID: 15146408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
